CTMX CytomX Therapeutics, Inc. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$3.24

Period return

-2.10 (-39.33%)

Volume

1.5M

2026-07-24O $3.34 H $3.38 L $3.2 C $3.24MA5 $3.37MA20 $3.63MA60 $3.55MA120 $4.25

6M · 125 barsYahoo Finance · USD2026-01-26 → 2026-07-24

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 05. 15.High2 months ago
13F 기관 보유 변화 — Point72 Asset Management, L.P.
신규 편입 · 포트폴리오 비중 0.07%
2026. 05. 15.High2 months ago
13F 기관 보유 변화 — TWO SIGMA INVESTMENTS, LP
신규 편입 · 포트폴리오 비중 0.01%
2025. 03. 31.Mediumlast year
2026년 1분기 실적 발표
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
2024. 09. 30.Medium2 years ago
2025년 3분기 실적 발표
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
2024. 06. 30.Medium2 years ago
2025년 2분기 실적 발표
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
2024. 03. 31.Medium2 years ago
2025년 1분기 실적 발표
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
2023. 09. 30.Medium3 years ago
2024년 3분기 실적 발표
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
2023. 06. 30.Medium3 years ago
2024년 2분기 실적 발표
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
2023. 03. 31.Medium3 years ago
2024년 1분기 실적 발표
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
2022. 09. 30.Medium4 years ago
2023년 3분기 실적 발표
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Rating & price-target changes

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). The company was founded in 2008 and is based in South San Francisco, California.

Sector: Healthcare
Industry

Quarter	Date	Time	EPS est.	EPS actual	Surprise	Rev. est.	Rev. actual	Status
FY2026 Q1	2025. 03. 31.	Time TBD	—	—	—	—	$50.92M	Reported
FY2025 Q3	2024. 09. 30.	Time TBD	—	—	—	—	$100.01M	Reported
FY2025 Q2	2024. 06. 30.	Time TBD	—	—	—	—	$66.58M	Reported
FY2025 Q1	2024. 03. 31.	Time TBD	—	—	—	—	$41.46M	Reported

#	Institution	Mandate	Shares	Value	Weight	Change	Position
1	Point72 Asset Management, L.P.	Point72 Asset Management, L.P.	7,875,390	$37.01M	0.07%	—	New position
2	Point72 Asset Management, L.P.	Point72 Asset Management, L.P.	5,189,538	$22.11M	0.04%	—	New position
3	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	2,710,156	$12.74M	0.01%	—	New position
4	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	1,560,755	$6.65M	0.01%	—	New position

CytomX Therapeutics, Inc.

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats